A Phase 2 interventional study of ABI-007 (Abraxane) and bevacizumab in Breast Neoplasms and Neoplasm Metastasis, sponsored by Celgene. Terminated at 40 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 18th largest by enrollment, is one of 9 that started in 2006, is one of 67 in phase 2, and was the 10th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Henan Cancer Hospital · Sites in China
Ages 18–70
University of Illinois at Chicago · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 79 · Phase 3 11 · Phase 4 4
First in 2001; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 208 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 108 interventional studies. Of the 66 that completed or were terminated, 41 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 108 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
44 studies in Breast Neoplasms by Bristol-Myers Squibb: 4 open now, 4 under way, 1 of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 44 studies in Breast Neoplasms by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2006, is one of 23 in phase 2, and was the 9th registered.
Bristol-Myers Squibb’s Breast Neoplasms studies by the year they started, since 2001.
3 of the studies testing Albumin-Bound Paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05420454Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Neoadjuvant Treatment of Breast Cancer | 2027-06-10 |
| NCT05420467Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Adjuvant Treatment of Breast Cancer | 2027-07-10 |
| NCT05287308Chinese Academy of Medical SciencesAdjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 44 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥ 1.5 x 10\^9cells/L; ≥ 100 x 10\^9 cells/L; ≥ 9 g/dL.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
260 mg/m\^2 every 3 weeks and 15 mg/kg bevacizumab every 3 weeks
Drug: ABI-007 (Abraxane) · Drug: bevacizumab
260 mg/m\^2 ABI-007 every 2 weeks and 10 mg/kg bevacizumab every 2 weeks
Drug: ABI-007 (Abraxane) · Drug: bevacizumab
130 mg/m\^2 ABI-007 weekly (without a week of 'rest') and 10 mg/kg bevacizumab every 2 weeks
Drug: ABI-007 (Abraxane) · Drug: bevacizumab
30 minute infusions
Also known as: Abraxane, paclitaxel bound to albumin
infusions
Also known as: Avastin
The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)
Using the RECIST response criteria version 1.0, the percent of participants achieving either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.
Time frame: Up to 43 months
Participant Counts of the Most Severe Grade for Absolute Neutrophil (ANC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) ANC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9L; Grade 2 = \<1.5 - 1.0\*10\^9L; Grade 3 = \<1.0 - 0.5\*10\^9L; Grade 4 = \<0.5\*10\^9L
Time frame: up to 54 months
Participant Counts of the Most Severe Grade for White Blood Cells (WBC) as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) WBC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal -3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L
Time frame: up to 54 months
Participant Counts of the Most Severe Grade for Platelet Counts as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) platelet counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L
Time frame: up to 54 months
Participant Counts of the Most Severe Grade for Hemoglobin Levels as Graded by the National Cancer Institute Common Terminology Criteria for Adverse Experience (NCI CTCAE v3)
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) hemoglobin levels were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100g/L; Grade 2 = \<100 - 80g/L; Grade 3 = \<80 - 65g/L; Grade 4 = \<65g/L
Time frame: up to 54 months
The Number of Participants With at Least One Dose Reduction for ABI-007
Participants with at least one dose reduction for ABI-007. ABI-007 (Abraxane) dose could be reduced according to protocol guidelines if the participant was experiencing toxicities. Participants were allowed two ABI-007 (Abraxane) dose reductions during the course of the trial. This outcome is considered to be both a safety and an efficacy outcome.
Time frame: Up to 53 months
The Number of Participants With at Least One Dose Delay for ABI-007
Participants with at least one dose delay for ABI-007. Treatment delays of no longer than 2 weeks allowed participants to recovery from acute toxicity. If treatment was delayed beyond 2 weeks, continuing treatment on protocol was at the physician's discretion, based upon the best interests of the participant. This outcome is considered to be both a safety and an efficacy outcome.
Time frame: Up to 53 months
The Number of Participants With a Dose Interruption of ABI-007
Number of participants who interrupted (omitted) a dose at some point in the treatment period. This outcome is considered to be both a safety and an efficacy outcome.
Time frame: Up to 53 months
Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0)
Using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), the percentage of participants achieving either * A complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or * A partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions or * Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for progressive disease.
Time frame: Up to 43 months (until progressed)
Kaplan Meier Estimate for Time to Disease Progression (TTP)
Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
Time frame: Up to 43 months (until progressed)
Kaplan Meier Estimate for Duration of Response
Duration of response was defined as the time from response to the time of disease progression for participants who achieve an objective confirmed complete (CR) or partial overall response (PR). Disease progression is based on the assessments by the investigator. Participants who did not have disease progression following a confirmed complete or partial target response were censored at the last known time that the participant was evaluated for response
Time frame: Up to 43 months (until progressed)
Kaplan Meier Estimate for Participant Survival
Participant survival was summarized using Kaplan-Meier estimate of the time of first dose of study drug to the last known time that the participant was alive. Participants that were alive at the end of follow-up would be censored at the last known time that the patient was alive.
Time frame: Up to 56 months
Kaplan Meier Estimate for Progression-Free Survival (PFS)
PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.
Time frame: up to 56 months
| Milestone | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Started | 75 | 54 | 79 |
| Completed | 0 | 0 | 0 |
| Not completed | 75 | 54 | 79 |
| Withdrew: Progressive disease | 28 | 18 | 27 |
| Withdrew: Unacceptable toxicity-related to trt | 21 | 24 | 32 |
| Withdrew: Adverse event-unrelated to treatment | 3 | 0 | 2 |
| Withdrew: Physician decision | 11 | 4 | 5 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 5 | 7 |
| Withdrew: Other | 6 | 3 | 5 |
Using the RECIST response criteria version 1.0, the percent of participants achieving either a complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions based on confirmed responses from the investigator assessment of best overall response during study treatment.
| Percent of Total Participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| The Percentage of Participants Confirmed Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 41 | 43 | 47 |
Using Response Evaluation Criteria in Solid Tumors (RECIST v1.0), the percentage of participants achieving either * A complete response (CR) defined as the disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation or * A partial response (PR) defined as at least a 30% decrease in the sum of the longest diameters of target lesions and no progression in non-target lesions or * Stable disease (SD) defined as neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for progressive disease.
| Percent of Total Participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Percentage of Participants With Stable Disease for ≥ 16 Weeks, or Complete or Partial Overall Response (i.e., Total Response) Based on Response Evaluation Criteria In Solid Tumors (RECIST v1.0) | 65 | 52 | 58 |
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) ANC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9L; Grade 2 = \<1.5 - 1.0\*10\^9L; Grade 3 = \<1.0 - 0.5\*10\^9L; Grade 4 = \<0.5\*10\^9L
| participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Grade 0 | 51 ± 1.569 | 34 ± 3.216 | 17 ± .750 |
| Grade 1 | 5 | 5 | 17 |
| Grade 2 | 2 | 6 | 17 |
| Grade 3 | 3 | 4 | 17 |
| Grade 4 | 2 | 0 | 2 |
Time to progression was defined as the time from the first dose of study drug to the start of progression. Participants that did not have progression were censored at the last known time the patient was evaluated for progression. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion.
| Months | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Kaplan Meier Estimate for Time to Disease Progression (TTP) | 8.0 (7.0 to 10.3) | 6.3 (5.3 to 8.0) | 9.0 (7.2 to 11.1) |
Duration of response was defined as the time from response to the time of disease progression for participants who achieve an objective confirmed complete (CR) or partial overall response (PR). Disease progression is based on the assessments by the investigator. Participants who did not have disease progression following a confirmed complete or partial target response were censored at the last known time that the participant was evaluated for response
| Months | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Kaplan Meier Estimate for Duration of Response | 10.3 (8.0 to 12.3) | 8.0 (5.5 to 13.4) | 9.9 (7.7 to 15.7) |
Participant survival was summarized using Kaplan-Meier estimate of the time of first dose of study drug to the last known time that the participant was alive. Participants that were alive at the end of follow-up would be censored at the last known time that the patient was alive.
| Months | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Kaplan Meier Estimate for Participant Survival | 21.3 (19.5 to 26.6) | 19.0 (15.0 to 28.1) | 23.7 (18.2 to 31.0) |
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) WBC counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal -3.0\*10\^9/L; Grade 2 = \<3.0 - 2.0\*10\^9/L; Grade 3 = \<2.0 - 1.0\*10\^9/L; Grade 4 = \<1.0\*10\^9/L
| participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Grade 0 | 47 | 30 | 11 |
| Grade 1 | 9 | 14 | 21 |
| Grade 2 | 6 | 5 | 26 |
| Grade 3 | 2 | 0 | 11 |
| Grade 4 | 0 | 0 | 1 |
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) platelet counts were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 75.0\*10\^9/L; Grade 2 = \<75.0 - 50.0\*10\^9/L; Grade 3 = \<50.0 - 25.0\*10\^9/L; Grade 4 = \<25.0\*10\^9/L
| participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Grade 0 | 60 | 39 | 64 |
| Grade 1 | 2 | 10 | 4 |
| Grade 2 | 1 | 0 | 1 |
| Grade 3 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 |
Myelosuppression is a decrease in the ability of the bone marrow to produce blood cells. The lowest measured (nadir) hemoglobin levels were graded using NCI CTCAE version 3: Grade 0 = within normal limits; Grade 1 = \< lower limit of normal - 100g/L; Grade 2 = \<100 - 80g/L; Grade 3 = \<80 - 65g/L; Grade 4 = \<65g/L
| participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Grade 0 | 41 | 25 | 13 |
| Grade 1 | 17 | 18 | 33 |
| Grade 2 | 6 | 6 | 19 |
| Grade 3 | 0 | 0 | 4 |
| Grade 4 | 0 | 0 | 1 |
Participants with at least one dose reduction for ABI-007. ABI-007 (Abraxane) dose could be reduced according to protocol guidelines if the participant was experiencing toxicities. Participants were allowed two ABI-007 (Abraxane) dose reductions during the course of the trial. This outcome is considered to be both a safety and an efficacy outcome.
| Participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| The Number of Participants With at Least One Dose Reduction for ABI-007 | 36 | 32 | 53 |
Participants with at least one dose delay for ABI-007. Treatment delays of no longer than 2 weeks allowed participants to recovery from acute toxicity. If treatment was delayed beyond 2 weeks, continuing treatment on protocol was at the physician's discretion, based upon the best interests of the participant. This outcome is considered to be both a safety and an efficacy outcome.
| Participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| The Number of Participants With at Least One Dose Delay for ABI-007 | 40 | 27 | 68 |
Number of participants who interrupted (omitted) a dose at some point in the treatment period. This outcome is considered to be both a safety and an efficacy outcome.
| Participants | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| The Number of Participants With a Dose Interruption of ABI-007 | 2 | 0 | 0 |
PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause) whichever occurred first. Participants that did not have progression or have not died were censored at the last known time the participant was progression free. Participants that initiate other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.
| months | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| Kaplan Meier Estimate for Progression-Free Survival (PFS) | 7.7 (7.3 to 8.8) | 6.3 (5.3 to 8.0) | 8.8 (5.8 to 9.9) |
Collected over Up to 54 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 260 mg/m^2 ABI-007 Every 3 Weeks | — | 22/75 (29.3%) | 75/75 (100%) |
| 260 mg/m^2 ABI-007 Every 2 Weeks | — | 16/54 (29.6%) | 54/54 (100%) |
| 130 mg/m^2 ABI-007 Weekly | — | 32/79 (40.5%) | 78/79 (98.7%) |
| Event | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 2/75 | 2/54 | 5/79 |
| VomitingGastrointestinal disorders | 1/75 | 1/54 | 4/79 |
| DiarrhoeaGastrointestinal disorders | 0/75 | 0/54 | 3/79 |
| NeuropathyNervous system disorders | 0/75 | 2/54 | 2/79 |
| Cardiac failure congestiveCardiac disorders | 2/75 | 0/54 | 0/79 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/75 | 1/54 | 2/79 |
| AnaemiaBlood and lymphatic system disorders | 0/75 | 0/54 | 2/79 |
| Mucosal inflammationGeneral disorders | 0/75 | 0/54 | 2/79 |
| PyrexiaGeneral disorders | 0/75 | 0/54 | 2/79 |
| DiverticulitisInfections and infestations | 0/75 | 0/54 | 2/79 |
| Event | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly |
|---|---|---|---|
| FatigueGeneral disorders | 55/75 | 43/54 | 64/79 |
| AlopeciaSkin and subcutaneous tissue disorders | 49/75 | 35/54 | 53/79 |
| NauseaGastrointestinal disorders | 37/75 | 36/54 | 40/79 |
| DiarrhoeaGastrointestinal disorders | 24/75 | 24/54 | 43/79 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 32/75 | 23/54 | 42/79 |
| ConstipationGastrointestinal disorders | 30/75 | 28/54 | 38/79 |
| Peripheral sensory neuropathyNervous system disorders | 34/75 | 24/54 | 36/79 |
| NeuropathyNervous system disorders | 34/75 | 24/54 | 34/79 |
| NeutropeniaBlood and lymphatic system disorders | 18/75 | 9/54 | 31/79 |
| RashSkin and subcutaneous tissue disorders | 20/75 | 17/54 | 31/79 |
| Age, Categorical(Participants) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 53 | 41 | 63 | 157 |
| >=65 years | 22 | 13 | 16 | 51 |
| Age, Customized(Years) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| Median | 59.0 (29.0 to 80.0) | 56.0 (36.0 to 79.0) | 56.0 (32.0 to 85.0) | 57.0 (29.0 to 85.0) |
| Sex: Female, Male(Participants) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| Female | 75 | 54 | 79 | 208 |
| Male | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| Asian | 1 | 0 | 1 | 2 |
| Black, of African Heritage | 11 | 13 | 19 | 43 |
| White, Non-Hispanic and Non-Latino | 52 | 31 | 45 | 128 |
| White, Hispanic or Latino | 8 | 10 | 14 | 32 |
| Other (not specified) | 3 | 0 | 0 | 3 |
| Weight(kilograms) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| Median | 72.9 (41.8 to 119.5) | 70.2 (41.4 to 145.0) | 73.1 (46.0 to 167.8) | 72.2 (41.4 to 167.8) |
| Menopausal status(Participants) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| Pre-menopausal | 11 | 11 | 16 | 38 |
| Post-menopausal | 64 | 43 | 63 | 170 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| 0 | 43 | 33 | 48 | 124 |
| 1 | 29 | 17 | 27 | 73 |
| 2 | 3 | 4 | 4 | 11 |
| 3 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 |
| Time from Primary Diagnosis to Study Entry(Years) | 260 mg/m^2 ABI-007 Every 3 Weeks | 260 mg/m^2 ABI-007 Every 2 Weeks | 130 mg/m^2 ABI-007 Weekly | Total |
|---|---|---|---|---|
| Median | 4.320 (0.025 to 16.901) | 3.127 (0.041 to 23.932) | 2.579 (0.022 to 21.065) | 2.983 (0.022 to 23.932) |
1 further baseline measures are reported on the registry.
Ran from Feb 2006 to primary completion in Jul 2010, 53 months.
Results were first posted in Mar 2012, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Bevacizumab